Edition:
United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

123.38USD
24 Mar 2017
Change (% chg)

$0.16 (+0.13%)
Prev Close
$123.22
Open
$123.72
Day's High
$124.13
Day's Low
$122.95
Volume
2,845,493
Avg. Vol
4,250,692
52-wk High
$127.64
52-wk Low
$94.42

Latest Key Developments (Source: Significant Developments)

Celgene Reports Results of Two Studies for Revlimid in Myeloma
Tuesday, 6 Dec 2016 04:00pm EST 

Celgene Corp : Phase III studies present additional evidence for REVLIMID® (lenalidomide) as maintenance therapy in multiple myeloma .Decision on European Union (EU) application for REVLIMID is expected in first half of 2017.  Full Article

Acetylon Pharmaceuticals entered into an agreement to be acquired by Celgene Corporation
Friday, 2 Dec 2016 02:33pm EST 

Acetylon Pharmaceuticals : Acetylon Pharmaceuticals -Regenacy Pharmaceuticals to be launched by Acetylon Pharmaceuticals and Celgene Corporation agrees to complete acquisition of acetylon . Acetylon Pharmaceuticals - entered into an agreement to be acquired by Celgene Corporation . Acetylon Pharmaceuticals - financial terms of acquisition are not being disclosed . Acetylon- key members of co executive team will join Regenacy, which will operate out of Acetylon's former headquarters in Boston's Seaport District . Acetylon Pharmaceuticals - prior to consummation of acquisition, Acetylon will spin out a new company, Regenacy Pharmaceuticals, LLC .Acetylon Pharma-Regenacy will receive worldwide rights to co's phase 2 selective histone deacetylase 6 (HDAC6) inhibitor, ricolinostat, among others.  Full Article

MaRS Innovation announces acquisition of first compound from Triphase by Celgene
Monday, 21 Nov 2016 10:32am EST 

MaRS Innovation: Triphase accelerator to sell assets relating to Marizomib to Celgene, via affiliate, for undisclosed amount .MaRS Innovation announces acquisition of first compound from portfolio company triphase by Celgene.  Full Article

Triphase Accelerator says Celgene will buy co's assets related to marizomib
Thursday, 17 Nov 2016 08:21pm EST 

Triphase Accelerator: says Celgene Corp, through an affiliate, has acquired co's assets related to its proteasome inhibitor, marizomib . under terms of agreement, Celgene will make an upfront payment plus additional regulatory, approval and sales milestone payments . specific financial terms were not disclosed . says Celgene will pay it to complete ongoing clinical studies with marizomib .Triphase Accelerator announces acquisition of its first compound, marizomib, by Celgene Corporation.  Full Article

Celgene Corp reports 12.3 pct stake in CRISPR Therapeutics AG - SEC filing
Monday, 31 Oct 2016 04:58pm EDT 

Celgene Corp :Celgene Corp reports 12.3 percent stake in CRISPR Therapeutics Ag as of October 24 - SEC filing.  Full Article

Celgene files for potential mixed shelf offering
Thursday, 27 Oct 2016 04:05pm EDT 

Celgene Corp : Files for potential mixed shelf; size not disclosed - sec filing Source: http://bit.ly/2eg2oOZ Further company coverage: [CELG.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Celgene & Agios collaborates with Abbott to develop diagnostic tests for leukemia
Wednesday, 12 Oct 2016 07:49am EDT 

Abbott Laboratories : Celgene and Agios announce collaborations with Abbott for diagnostic identification of IDH mutations in AML . Celgene - companion diagnostic technology to be utilized with Enasidenib, AG-120 development programs for relapsed/refractory acute myeloid leukemia .Celgene-Agreements with abbott to develop,commercialize companion diagnostic tests on Abbott's M2000 realtime system to identify IDH mutations in AML.  Full Article

Celgene reports 8.1 pct passive stake in Oncomed Pharmaceuticals
Wednesday, 24 Aug 2016 06:23am EDT 

Oncomed Pharmaceuticals :Celgene Corporation reports 8.1 pct passive stake in Oncomed Pharmaceuticals Inc as of August 23, 2016 - SEC filing.  Full Article

Celgene reports Q2 GAAP earnings per share $0.75
Thursday, 28 Jul 2016 07:30am EDT 

Celgene Corp : Celgene reports second quarter 2016 operating and financial results . Q2 adjusted earnings per share $1.44 . Q2 revenue $2.754 billion versus I/B/E/S view $2.7 billion . Q2 GAAP earnings per share $0.75 . Q2 earnings per share view $1.38 -- Thomson Reuters I/B/E/S . Abraxane sales for Q2 were $249 million, a 2 percent increase year-over-year . Sees 2016 adjusted diluted EPS $5.70 to $5.75 . Sees 2016 revlimid net sales about $6.8 billion . FY2016 earnings per share view $5.70, revenue view $11.01 billion -- Thomson Reuters I/B/E/S . 2016 net product sales guidance for Pomalyst/Imnovid, Abraxane and Otezla remain unchanged . 2016 guidance updated: revlimid and total net product sales; EPS . Sees 2016 adjusted operating margin approximately 54.0% . Sees 2016 GAAP diluted eps $3.82 to $4.05 .Sees 2016 total net product sales about $11 billion.  Full Article

Celgene and LYSARC provide update on the phase III study
Monday, 25 Jul 2016 04:30pm EDT 

Celgene Corp : Interim analysis of overall survival, a key secondary endpoint, showed no benefit in revlimid . Based upon these interim results, Celgene does not currently plan to seek approval for this indication . Says is also exploring multiple clinical candidates in non-hodgkin lymphomas and T-cell lymphomas . Celgene and LYSARC provide update on the phase III 'remarc' study of revlimid maintenance treatment in patients with diffuse large B-cell lymphoma responding to first-line R-chop therapy .Remarc achieved primary endpoint of a statistically significant improvement in progression-free survival for patients receiving revlimid.  Full Article

More From Around the Web

BRIEF-Oncolytics Biotech enters collaboration with Myeloma UK and Celgene

* Oncolytics biotech enters into first-in-class collaboration with Myeloma UK and Celgene using Reolysin in combination with Imnovid or Revlimid in patients with Myeloma